Global Biosimilar Market & Pipeline Examined by CBR Pharma Insights in Its Topical Report Available at MarketPublishers.com

21 Apr 2017 • by Natalie Aster

LONDON – Complex requirements associated with biological drugs manufacturing also apply to biosimilars, this has been a considerable restraint to the further growth of the biosimilars market. The major challenge has been the knowledge gap (biosimilars are developed under), which is the result of proprietary of innovator product information; therefore, biosimilar manufacturers have to adopt a reverse engineering process.

Enormous commercial opportunities are expected to emerge in the biosimilars market in the coming years, in the wake of the number of high-revenue-generating biologics that will go off the patent till 2020 along with lucrative revenue forecasts for biosimilars in the late stage of the development.

At present, favourable government support for the development of the biosimilars market is increasing across the major geographies, given the cost-effective opportunities offered by these products to national healthcare budgets.

Topical study “Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design” prepared by CBR Pharma Insights offers in-depth insights into the global landscape of the biosimilars market as well as covers the biosimilars pipeline in detail. The report contains an insightful assessment of the key challenges and opportunities, reviews the recent initiatives taken by the key market players, discusses the burning issues, describes the current regulatory framework and sheds light on the latest biosimilars approvals. The report is a reliable source of data on different biosimilars for a broad spectrum of therapy areas. It explores the market trends across the top geographical markets and gives access to forecasts through 2020.

Moreover, this report offers a clear picture of the world’s biosimilars commercial and R&D landscape, discloses info on production processes, reviews the ways to mitigate development risks, offers an overview of lucrative strategies adopted by top PharmaCos and provides understanding of the future prospects of the biosimilars market.

The CBR Pharma Insights catalogue contains many other in-demand reports prepared by this publisher.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com